GTEC.OB

[gnlbigte]

Entry at 0.13 and exit at 0.15 yesterday. Was watching it gap up today morning. Then watched the consolidation today. Will buy again on dip tomorrow. This moves fast. China and merger news are good for this stock.

[setravis]

Seeing a thread on this ol' dog takes me back. I bought the top back in Feb 04 at .45. Sold half for a 35% loss and let the other half "run" which turned into a a 65% loss Would be nice to make back some of that loss. Not convinced that now is the time to jump back in. If RSI can break resistance at 50 on the weekly for the first time in two years, I might throw some money at it. This is the third test of 50 in the last 18 months. Watching...

This "old dog" been running like a pup....

Technicals
Record Volume
Record Price High
Most Actives
Percentage Gainer

Last Price Quote is:
129.48%above 13-day EMA
303.55%above 50-day EMA

[la-onda]

new 52 week high 

[la-onda]

I am in @ 0.4$ 

Board of Directors Conduct Quarterly Meeting in Beijing, China to Assess Accomplishments and Direction of GTEC
Wednesday March 15, 6:30 am ET

BEIJING, March 15, 2006 (PRIMEZONE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News), a business development and marketing firm that specializes in procuring opportunities in China, released a summary of the quarterly Board of Directors meeting conducted in Beijing last week. Directors were unanimous that the Company had reached the most promising and sound position in its 4-year history, with profitability a distinct possibility for the quarter ending March 2006.

Gary L. Wolfson, Chairman and CEO, observed: ``The Company is in its best position since its inception. It has virtually retired the $2 million debt it incurred through an SB2 registration in 2004. Cash and cash equivalents have reached nearly $3 million. Perhaps most importantly, the Genesis business model, a specialized merger and acquisitions program for qualified Chinese companies, appears to have placed the Company in a position of sustained profitability. Our loyal shareholders, who endured a difficult 2005, as management totally revamped and reorganized Genesis, are reaping the benefits of our efforts and their own patience and confidence.''

Summarizing other achievements and goals, the Company has:

-- Reached a sound position with ample cash reserves and a low
    burn rate to operate efficiently for the foreseeable future. It
    does not anticipate engaging in any fund-raising activities in
    the current fiscal year.  Near-term profitability seems
    increasingly likely. 
-- Refined its business model that specializes in marketing Merger
    and Acquisition products to qualified Chinese companies in
    accessing Western markets. These companies are all profitable,
    have significant cash on hand, and revenues between $12 million
    to $80 million.  As this program has evolved, the estimated
    financial benefits for Genesis range from a quarter of a
    million dollars to $5 million per project.
-- Succeeded in contracting with The Jin Ma Group in creating
    Gold Horse International, Inc., a private U.S. corporation
    designed to become publicly trading during 2006.  This
    construction, real estate and hospitality enterprise has
    recorded annual revenues exceeding $20 million and net profit
    above $2 million.  Other prospective client companies are
    reaching final contract stages, and such achievements could be
    announced in the coming weeks.
-- Benefited from the increased value of previous business
    development projects in China, including the performance of SunWin
    Nutriceuticals (OTC BB:SUWN.OB - News), Dragon Capital (Other OTC:DRGV.PK - News)
    and others. The value of such holdings, in cash, stock and
    warrants, now exceeds $3 million.
-- Advanced its negotiations with a merger partner in Western China
    that has $40 million in assets, over $60 million in revenues, and
    nearly $7 million in net profits. After five extensive meetings in
    China and the U.S., the negotiations have reached the final due
    diligence and audit phases.  Management anticipates that this
    merger opportunity should be brought to a definitive conclusion in
    the next 60 days. Such a proposal would require a majority vote
    by the Board of Directors and the Company's shareholders.
-- Scheduled its Annual Shareholders Meeting in Beijing on
    Friday, May 19, 2006, to accommodate its increasing number of
    Chinese shareholders and to educate its Western shareholders
    concerning the opportunities and challenges of conducting
    business in the People's Republic of China. The China World
    Hotel (No. 1 Jianguomenwai Avenue) shall be the headquarters
    for the meeting.

[la-onda]

20 EMA support ??

[la-onda]

news out 

<Genesis Equity Partners Acquires Interest in Chinese Pharmaceutical Company
Tuesday March 21, 6:30 am ET
Popular Hypertension Drug Leads Array of Effective Medications

BOCA RATON, Fla., March 21, 2006 (PRIMEZONE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) announced that its subsidiary, Genesis Equity Partners, LLC, signed a contract with the Liang Fang Pharmaceuticals, Ltd., one of China's most respected and innovative drug development, medical device, and retail drug store enterprises.

Liang Fang reportedly grossed over $15.8 million in revenues, almost $ 2.6 million in net profits in 2005, plus net assets exceeding $ 7.5 million. For the past three fiscal years combined, Liang Fang's revenues exceeded a total of $ 31.2 million. Based on its first quarter sales for 2006, the Beijing-based manufacturer, which also has 10 retail outlets, forecasts an increase to over $20 million in revenues this year. Genesis Equity Partners will receive a significant equity position in Liang Fang and ongoing consulting fees for coordination and oversight of its U.S. business activities.

Among Liang Fang's best selling products, Valsartan Capsules are a medicine for primary hypertension or high blood pressure. Valsartan first came to market in America in 1996, known as Diovan. The Novartis AG version of the Diovan product generated almost 17 percent of that company's 2004 revenues from branded pharmaceuticals. Novartis predicted the drug might be its first to generate annual revenues of more than $5 billion.

Dr. Liu Zhongyi, CEO of Liang Fang, commented: ``In July 2001, the National Drug Administration authorized Liang Fang for the production of Valsartan. With increased production and marketing, we believe that it should dominate the Chinese market, where over nine percent of the population suffers from high blood pressure.

``Valsartan is just one example of the important and successful array of drugs that Liang Fang has acquired or developed and marketed over the years. Liang Fang intends to become a global brand, although the market in China is large enough to sustain our growth rate at over 40% annually. We realize that Western marketing is often the key to such success, and we intend to capitalize on Genesis's expertise and network in China, Latin America, and the United States.

``We selected Genesis because of its long history of success and expertise in China. We carefully studied its GEP merger and acquisition program, and believe that Liang Fang can flourish globally. In our evaluation, we also reviewed the performance of another Genesis Chinese client, SunWin Neutraceuticals (OTC BB:SUWN.OB - News), and we are confident that Liang Fang could exceed its success, as a U.S. publicly traded company,'' concluded Dr. Liu.

Dr. Shaohua Tan, the Genesis Director who negotiated the Liang Fang contract, added: ``We are enthused to add Liang Fang to the list of GEP clients. This month, Messrs. Wolfson and Clinton joined me in inspecting the world-class Liang Fang manufacturing plant and two of its Beijing retail stores. The Company's management, facilities and obvious growth potential impressed us immensely.

``Last month, we announced that Gold Horse International became the newest member of our innovative merger and acquisition program. Its market sector, construction and real estate development, ranks among the most active in China. Now, with Liang Fang, we are entering the health care and pharmaceutical arena, perhaps the fastest growing industry worldwide.''

Annual Shareholders Meeting scheduled on Friday, May 19, 2006, at 1 o'clock P.M. at the China World Hotel in Beijing, China, located at No. 1 Jianguomenwai Avenue; telephone (8610) 6505-2266, facsimile (8610) 6505-0828, email [email protected] and website http://www.shangri-la.com.

[setravis]

Press Release Source: Genesis Technology Group, Inc.


Genesis and Beijing Pharmaceuticals Partner Announce Four New Drugs and Revenues Increase
Thursday May 11, 6:30 am ET


BOCA RATON, Fla., May 11, 2006 (PRIMEZONE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) announced that Lotus Pharmaceuticals, Inc., its health care and pharmaceuticals partner in Beijing, has commenced programs to increase its 2006 revenues above $20 million with about 15% in net profits, to launch its new U.S. public corporation through a reverse merger, and to establish Lotus as a national brand in China. New facilities, manufacturing capability, and four drugs scheduled to come to market in the fall all contributed to the increased forecasts. Based on these revised projections and its significant equity stake in Lotus, Genesis estimates its own net gain could exceed $2 million.
At present, Lotus is undergoing an independent audit of its financial statements by a New York certified public accounting firm that will enable Genesis to create the publicly traded company, in which Genesis will have a percentage ownership, during this calendar year. Since March 2006, when Genesis Equity Partners acquired a significant interest in Lotus Pharmaceuticals, Inc., Lotus increased its revenues and profits forecasts by over 30% based on first quarter sales -- exceeding $5 million -- and these three major developments, announced last week:

-- Lotus opened its newly-built facilities to produce freeze-dry
    powder injections, small-volume injections and eye drops with
    total investments of $245,000, which passed the National GMP
    Certification with the Certificate Number G3452.

-- Exclusive new drug curing open-angle glaucoma, alpha-2 Receptor
    Excitant-brimonidine tartrate material and eye drops (Muxin) was
    approved by the State SFDA (registration number of approval: SDPD
    H20041215), and came to market in September; the sales in three
    months totaled RMB $244,000 with a profit of $100,000.

-- Levofloxacin Lactate Freeze-Dry Powder Injection (Junxin), the
    broad spectrum antibiotic ranks first on use level in the world
    was approved by the State SFDA (registration number of approval:
    SDPD H20050501), and also came into the market in September; the
    sales in three months was $400,000 with a profit of $134,000.

Dr. Liu Zhongyi, CEO of Lotus Pharmaceuticals, commented: ``Lotus is on track to become a U.S. publicly traded company in 2006. With Genesis as our equity partner and U.S. representative, we are confident that Lotus will be well received by investors. Our goal is to establish Lotus (known in China as Liang Fang) as one of the country's most prominent pharmaceutical companies. Future investment will not only expand Lotus's market nationally, but, ultimately, we believe that it could become an international brand.

``In addition to well-established Valsartan Capsules for the treatment of hypertension, Lotus has submitted the following new drugs for SFDA approval and marketing in China:



1. Broad spectrum antibiotic: Gatifloxacin Lactate Injection
    (Acceptance No.: CXHS0503239 Beijing and CXHS0503240 Beijing)

2. Broad spectrum antibiotic: Gatifloxacin Lactate Freeze-Dry Powder
    Injection (Acceptance No.: CXHS0503288 Beijing and CXHS0503289
    Beijing).

3. A new drug used to cure acute and chronic ambient circulatory
    disturbance, and ameliorate the low conation caused by cerebral
    infarction sequela and affective disturbance: Nicergoline
    Freeze-Dry Powder Injection (Acceptance No.: CYHS0506815 Beijing).

4. A new drug used to cure cerebral edema resulted from various
    courses of disease, swelling caused by wound or operation and
    venous return disturbance: Sodium Aescinate Freeze-Dry Powder
    Injection (Acceptance No.: CYHS0506816 Beijing and CYHS0506817
    Beijing).
 
Continued Dr. Liu: ``We anticipate these drugs coming to market in October 2006, and the impact on our sales should be substantial. On Friday, May 19, 2006, at the Genesis Annual Shareholders Meeting in Beijing, I will present a detailed report on the growth and future of Lotus Pharmaceuticals.''

Dr. Shaohua Tan, a member of the Genesis Board of Directors who oversees its China operations, repeated his explanation of the GEP program: ``These developments are a good example of the success of the Genesis business model. Basically, Genesis invests time, effort and money to secure a significant position in Chinese companies with experienced management and a history of success in China. The screening process is rigorous, and few candidates qualify to become GEP partners. Those that do then undergo an independent audit of their financial statements. After months of due diligence and contributions by our auditing, legal and management teams, we can launch these restructured and dynamic companies as U.S. publicly traded corporations.

``The value proposition is clear: the GEP partner companies offer assets, revenues and profits well beyond those available in the West at the costs and investment levels we can negotiate. Furthermore, with the likelihood of the revaluation of the yuan (Chinese dollar) against the U.S. dollar, most experts speculate that the value of such Chinese assets could increase above 25%; of course, this would concomitantly impact the revenues and profits at the same levels. We believe that Genesis has created a business model that could provide sustained profitability for our Company,'' Dr. Tan concluded.

Note: The Annual Shareholders Meeting has been scheduled for Friday, May 19, 2006, at 1 o'clock P.M. at the China World Hotel in Beijing, China, located at No. 1 Jianguomenwai Avenue; telephone (8610) 6505-2266, facsimile (8610) 6505-0828, email [email protected] and website http://www.shangri-la.com.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. (known in China as Liang Fang Pharmaceuticals, Ltd.) is a large comprehensive enterprise, which deals in an integration of the production, trade and retailing of pharmaceuticals. It possesses the most advanced pharmaceutical-making equipment now in China, workshops authenticated by the National GMP, a number of first-rate medicines and other types of medicines produced solely in this corporation, and a large group of high-tech personnel. Lotus covers a business and office area of 2,000 square meters and a storehouse of 1,000 square meters. Altogether there are four organs attached to this corporation handling respectively the scientific research on new medicine, the production, wholesale and retail of medicine. The new Lotus Pharmaceuticals website is under construction.

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. is a business development firm that fosters bilateral commerce between Western and Chinese companies. The Company has offices in the United States and China. A 75% owned subsidiary of Genesis, Genesis Equity Partners, LLC assists Chinese and Western companies in formulating strategies to increase equity value, while targeting Western stock exchanges as a source of capital and shareholder support. The core strength of GEP management is creating a first rate plan to create investor awareness and bring in long-term individual and institutional investors. GEP should create liquidity in the stock and gain investor awareness by using tested channels of communications by cogently articulating the companies' stories. GEP has built successful channels with expertise in screening and selecting Chinese companies that possess solid business histories and professional management, and North American public companies and shells that possess a shareholder base and a history of auditing and filing, as required by the US Securities & Exchange Commission. For more information, visit http://www.genesis-technology.net

Safe Harbor Statement

Certain statements set forth in this press release constitute ``forward-looking statements.'' Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words ``estimate,'' ``project,'' ``intend,'' ``forecast,'' ``anticipate,'' ``plan,'' ``planning,'' ``expect,'' ``believe,'' ``will likely,'' ``should,'' ``could,'' ``would,'' ``may'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an

indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
          Genesis Technology Group, Inc.
          Kenneth Clinton
          (561) 988-9880
          [email protected]


--------------------------------------------------------------------------------
Source: Genesis Technology Group, Inc.

[setravis]

Press Release Source: Genesis Technology Group, Inc.


Genesis Annual Shareholders Meeting Spotlights Company's Financial Strength, China Growth, and Future Success
Tuesday May 23, 7:00 am ET


BEIJING, May 23, 2006 (PRIMEZONE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News), a Chinese marketing and investment services company, conducted its Annual Shareholders Meeting on Friday, May 19th, at Beijing's China World Hotel. For those shareholders unable to attend, a synopsis follows:

-- The Company is cash flow positive and only growing stronger; its
    clients are increasing in numbers and quality. Management remains
    confident that the Company continues on the right course, as
    profitability and sustainability remain the primary goal. The next
    quarterly report should support this commitment.

-- The opportunity for merger has been a key focus since December
    2005. Auditing issues, not to mention the expense of an audit has
    been a concern for both parties. However, several other merger
    opportunities have presented themselves to Genesis, including
    another Chinese company that had over $300 million in revenues last
    year.  Possible merger candidates with Genesis should be nothing
    short of enormous, from financial strength, market sector, to
    management.  Director Shaohua Tan concluded: "We are in an
    excellent position. Our Chinese network and our growing financial
    strength have provided us with this luxury.  Completing a merger
    that will enhance our shareholders' position is a top priority.
    For good measure, management must revise its previous timeline
    forecast."

-- The progress of Gold Horse International and Lotus Pharmaceuticals,
    Genesis' equity partners, is excellent.  In less than 90 days, both
    companies could be trading, thus dramatically increasing the net
    asset value of Genesis.  Genesis provides a full circle, turn-key
    service for partner companies.  Genesis could have an admirable
    equity position in five to 10 new public companies within the next
    nine months in addition to its six current investments.   When
    partner companies begin to increase in market cap, as anticipated,
    the net asset value of Genesis will increase as well.  Prospective
    investors can invest in Genesis, thus investing in as many as 10
    different companies.  If investors determine to invest only in
    Lotus Pharmaceuticals, for example, Genesis would still receive
    direct benefit.

-- From February 1st to the third week of May, the Company increased
    in value about 500%.  Seldom do public -- especially NASDAQ Bulletin
    Board -- companies show straight line growth, as GTEC rose as much
    as 1000% during the interim period. Management is unconcerned
    about the vagaries of the day-trading market, as it is only
    increasingly confident about the Company's successful business
    model and future achievements. Management adheres to "let the
    market be your guide" and that the long view is the only
    significant perspective.


Chairman Gary Wolfson summarized the two hour, bilingual summit: ``In our first four years as a listed company, 2006 is, by far, our best year to date. We are confident that our model will only improve, providing an excellent return to shareholders. We could not be more encouraged. We discussed the three major interest points: the Company's performance since February 1st, the status of the avidly discussed merger opportunity, and -- perhaps most important -- what we believe the future holds.''

Kenneth Clinton, Genesis President, said: ``Our New York auditor completed a 3-week visit to China, and our CFO joined us here now. These companies should be listed companies in the U.S. -- to the benefit of Genesis, Gold Horse and Lotus shareholders -- in 2006. Of course, we expect to announce several new Chinese clients promptly that could, in turn, be trading by year end.''

A full power point of the proceedings is available on the company's website at http://www.genesis-technology.net

About Genesis Technology Group, Inc.:

Genesis Technology Group, Inc. markets, builds, and obtains equity interest in mid-size and large Chinese companies. The Company has created successful profit centers by incubating Chinese companies in a wide range of sectors, creating ``partner companies.'' The team at Genesis dedicates its expertise and capital resources to expand the potential of these enterprises. To help drive the success and profitability of such partner companies, Genesis provides abundant resources and proficiency to maximize their leadership potential in China and helps position them to create high-margins, with increasing and predictable earnings. The Company has offices in the United States and China. For more information, visit http://www.genesis-technology.net.

Safe Harbor Statement

Certain statements set forth in this press release constitute ``forward-looking statements.'' Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words ``estimate,'' ``project,'' ``intend,'' ``forecast,'' ``anticipate,'' ``plan,'' ``planning,'' ``expect,'' ``believe,'' ``will likely,'' ``should,'' ``could,'' ``would,'' ``may'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
          Genesis Technology Group, Inc.
          Kenneth Clinton
          (561) 988-9880


--------------------------------------------------------------------------------
Source: Genesis Technology Group, Inc.

[setravis]

Press Release Source: Genesis Technology Group, Inc.


Genesis Technology Group, Inc. Releases Audited Annual Report with $2.9 Million in Net Income and Assets of $7.2 Million
Tuesday January 16, 5:58 pm ET


BOCA RATON, Fla., Jan. 16, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) released its Annual Report for fiscal year 2006, the 10-KSB filing, as audited by Sherb & Company of New York. The Company revealed net income of $2.9 million and assets of $7.2 million, making the year its most successful in history. This equates to net income of $0.03 per common share, fully diluted.


Mr. Adam Wasserman, who has served as the Genesis Chief Financial Officer since October 2001, reported: ``The financial condition of the Company continues to show progress. For the year ended September 30, 2006, we reported net income of $2,909,606 or $0.03 per common share, compared to a net loss of $(3,726,929) or $(0.06) per common share for the year ended September 30, 2005, a positive increase of $6,636,535.

``As of September 30, 2006, the Company's total assets amounted to $7,231,773, compared to $1,719,042 on September 30, 2005. Our total operating expenses decreased by $1,066,815 compared to the previous 12 months of operation. Furthermore, through the sale of marketable securities that the Company had previously received for services rendered, our cash and trading marketable securities totaled $1,194,175 on September 30, 2006,'' concluded Mr. Wasserman.

Mr. Gary L. Wolfson, Chief Executive Office, added: ``Management embarked on a difficult task over two years ago to revamp and revitalize our Company. It required hard decisions and decisive action, and we believe the results are starting to be realized. We have assembled teams in the U.S. and China that maintain the highest levels of professionalism and possess the skills to capitalize on the challenges and opportunities uniquely provided by the Chinese economy. Can Genesis sustain such profitability and growth? That is the real challenge. The 'Year of the Golden Pig' graces the Chinese calendar only once every 60 years, and starting New Year's Day, February 18, 2007, we will see if that anticipated period of great prosperity includes Genesis.''

About Genesis Technology Group, Inc.

Genesis Technology Group, Inc. (``Genesis'' or ``Genesis China'') is a business development and marketing firm that specializes in advising and providing a turn key solution for Chinese small and mid-sized companies entering Western markets. We dedicate our expertise and capital resources to expand the potential of Chinese partner companies. We provide the marketing strategy, counsel, and plans to support our clients' business, financial, or marketing goals. We work closely with top management to define their strategy and business model to develop effective tactics to support business development. Our business mission is to create substantial, incremental stockholder value for emerging growth companies by executing strategy-driven programs that professionally incubate and mature Chinese companies and prepare them for Western markets. For more information, visit http://www.genesis-china.net.

Safe Harbor Statement

Certain statements set forth in this press release constitute ``forward-looking statements.'' Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words ``estimate,'' ``project,'' ``intend,'' ``forecast,'' ``anticipate,'' ``plan,'' ``planning,'' ``expect,'' ``believe,'' ``will likely,'' ``should,'' ``could,'' ``would,'' ``may,'' or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
          Genesis Technology Group, Inc.
          Kenneth L. Clinton, President
          (561) 988-9880
          Fax: (561) 988-9890
          [email protected]


--------------------------------------------------------------------------------
Source: Genesis Technology Group, Inc.


It's been some time in between post.......

[cipisek]

Here is news about GTEC. OB http://biz.yahoo.com/pz/070403/116511.html

[cipisek]

Hi

[cipisek]

Do we go up? Yes, we do!!!

http://biz.yahoo.com/pz/070418/117515.html

Press Release Source: Genesis Technology Group, Inc.


Genesis' Pharmaceutical Partner Releases Audited Annual Report with $4.1 Million in Net Profits
Wednesday April 18, 6:30 am ET


BEIJING, April 18, 2007 (PRIME NEWSWIRE) -- Genesis Technology Group, Inc. (OTC BB:GTEC.OB - News) announced that its Chinese pharmaceutical partner yesterday released its 2006 audited annual report. Lotus Pharmaceuticals, Inc. (OTC BB:LTUS.OB - News) revealed gross revenues of $36 million, net profits of $4.1 million and net assets of $20.6 million.
Dr. Shaohua Tan, Genesis' Director headquartered in Beijing, also offered an update for the Genesis private-to-public program that operates under the name Genesis Equity Partners, LLC (GEP), a group of majority-owned subsidiaries, individually designated for each Chinese partner company. Among Dr. Tan's key comments were:



1.  Lotus has shown good progress since becoming a GEP partner company
     last March. GTEC owns 6.7 million LTUS common shares of the 50
     million outstanding. Genesis maintains an active role in Lotus
     operations and strategy, having appointed three members on its
     board of directors, also serving in an ongoing consulting
     capacity overseeing its U.S. office and activities.

2.  Gold Horse International, Inc. (GHI) continues to advance to
     public company status. Its official U.S. audit required an
     updating through December 2006, which has now been completed by
     Kabani & Company. GHI has moved into the late stages of the GEP
     private-to-public program.

3.  The other three GEP partner companies bear U.S. designations and
     have entered the exacting U.S. auditing stage. China Environmental
     Technologies, Oriental Health Beverages, and Sino Steel Structures
     could produce significant profits and assets for Genesis, if
     those Chinese companies' U.S. audits and legal due diligence
     confirm internal reporting. With each company, Genesis would play
     an active role in its management and strategy to attain its
     goals and expansion.

4.  The revised rules and regulations of the China Securities
     Regulatory Commission (CSRC), invoked August-September 2006,
     have placed a significant additional burden on GEP and its
     competitors. While the full impact is still being determined,
     it seems apparent that CSRC rulings have (a) increased the costs
     and risks, (b) created additional steps with central government
     involvement, and (c) delayed the process to complete the
     private-to-public process. Dr. Tan closed by emphasizing that
     "any future changes or revisions by the CSRC could have a major
     impact on the GEP business model."

[cipisek]

Hi

[cipisek]

Nice chart

[cipisek]

We go up